Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study

BackgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) are available.MethodsThis multicenter, retrospective study aimed at evalu...

Full description

Bibliographic Details
Main Authors: Alessandro Parisi, Alessio Cortellini, Olga Venditti, Roberto Filippi, Lisa Salvatore, Giampaolo Tortora, Michele Ghidini, Olga Nigro, Fabio Gelsomino, Ina Valeria Zurlo, Claudia Fulgenzi, Pasquale Lombardi, Susana Roselló Keränen, Ilaria Depetris, Riccardo Giampieri, Cristina Morelli, Pietro Di Marino, Francesca Romana Di Pietro, Nicoletta Zanaletti, Pasquale Vitale, Ingrid Garajova, Gian Paolo Spinelli, Federica Zoratto, Michela Roberto, Angelica Petrillo, Giacomo Aimar, Leonardo Patruno, Carla D’Orazio, Corrado Ficorella, Claudio Ferri, Giampiero Porzio
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
MCRC
FOLFOX
FOLFIRI
cetuximab
panitumumab
maintenance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.712053/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.712053/full

Similar Items